Chemokines - Their role in immunotherapy for intraocular inflammation

Ocular Immunology and Inflammation

Volumn 11, Issue 2, 2003, Pages 83-90

  Kawashima, Hidetoshi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Chemokine; Cytokine; Immunotherapy; Intraocular inflammation; TNF

Indexed keywords

ALPHA CHEMOKINE; CHEMOKINE; CHEMOKINE RECEPTOR CXCR4; COLCHICINE; CX3C CHEMOKINE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; METHOTREXATE; MIZORIBINE; MONOCYTE CHEMOTACTIC PROTEIN 1; PREDNISOLONE; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANTIBODY PRODUCTION; AUTOIMMUNE DISEASE; CLINICAL TRIAL; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INFECTION RISK; INFLAMMATION; LEUKOCYTE MIGRATION; OPTIC NERVE DISEASE; PIGMENT EPITHELIUM; PROTEIN FAMILY; PROTEIN TARGETING; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; TUBERCULOSIS; UVEITIS; VISUAL ACUITY;

ANIMALS; CHEMOKINES; ENDOPHTHALMITIS; HUMANS; IMMUNOTHERAPY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0041875007     PISSN: 09273948     EISSN: None     Source Type: Journal    
DOI: 10.1076/ocii.11.2.83.15917     Document Type: Review

References (30)

1. Baggiolini M, Dewald B, Moser B. Human chemokines - an update. Annu Rev Immunol. 1997;15:675-705.
2. Yoshimura T, Matsushima K, Taknaka S, Robinson EA, Appella E, Oppenheim JJ, Leonard EJ. Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci. 1987;84:9233-9237.
3. Matsushima K, Larsen CD, DuBois GC, Oppenheim JJ. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med. 1989;169:1485-1490.
4. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, Springer TA. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature. 1996;382:829-833.
5. Baggiolini M, Loetscher P. Chemokines in inflammation and immunity. Immunol Today. 2000;21:418-420.
6. Faunce DE, Sonoda KH, Stein-Streilein J. MIP-2 recruits NKT cells to the spleen during tolerance induction. J Immunol. 2001;166:313-321.
7. Faunce DE, Stein-Streilein J. NKT cell-derived RANTES recruits APCs and CD8+ T cells to the spleen during the generation of regulatory T cells in tolerance. J Immunol. 2002;169:31-38.
8. Okada AA. Drug therapy in Behçet's disease. Ocular Immunol Inflamm. 2000;8:85-91.
9. Molad Y. Update on colchicine and its mechanism of action. Curr Rheumatol Rep. 2002;4:252-256.
10. Adamus G, Manczak M, Machnicki M. Expression of CC chemokines and their receptors in the eye in autoimmune anterior uveitis associated with EAE. Invest Ophthalmol Vis Sci. 2001;42:2894-2903.
11. Mo JS, Matsukawa A, Ohkawara S, Yoshinaga M. Role and regulation of IL-8 and MCP-1 in LPS-induced uveitis in rabbits. Exp Eye Res. 1999;68:333-340.
12. Mo JS, Matsukawa A, Ohkawara S, Yoshinaga M. CXC chemokine GRO is essential for neutrophil infiltration in LPS-induced uveitis in rabbits. Exp. Eye Res. 2000;70:221-226.
13. Becker MD, O'Rairke LM, Blackman WS, Planck SR, Rosenbaum JT. Reduced leukocyte migration, but normal rolling and arrest, in interleukin-8 receptor homologue knockout mice. Invest Ophthalmol Vis Sci. 2000;41:1812-1817.
14. Verma MJ, Mukaida N. Vollmer-Conna U, Matsushima K, Lloyd A, Wakefield D. Endotoxin-induced uveitis is partially inhibited by anti-IL-8 antibody treatment. Invest Ophthalmol Vis Sci. 1999;40:2465-2470.
15. Foxman EF, Zhang M, Hurst SD, Muchamuel T, Shen D, Wawrousek EF, Chan CC, Gery I. Inflammatory mediators in uveitis: differential induction of cytokines and chemokines in Th1- versus Th2-mediated ocular inflammation. J Immunol. 2002;168:2483-2489.
16. Enzmann V, Kaufmann A, Hollborn M, Wiedemann P, Gemsa D, Kohen L. Effective chemokines and cytokines in the rejection of human retinal pigment epithelium (RPE) cell grafts. Transpl Immunol. 1999;7:9-14.
17. Qian Y, Dekaris I, Yamagami S, Dana MR. Topical soluble tumor necrosis factor receptor type I suppresses ocular chemokine gene expression and rejection of allogeneic corneal transplants. Arch Ophthalmol. 2000;118:1666-1671.
18. Torres PF, Slegers TP, Peek R, van Rcoijen N, van der Gaeg R, Kijestza A, de Vos AF. Changes in cytokine mRNA levels in experimental corneal allografts after local clodronate-liposome treatment. Invest Ophthalmol Vis Sci. 1999;40:3194-3201.
19. Colvin BL, Thomson AW. Chemokines, their receptors, and transplant outcome. Transplant. 2002;74:149-155.
20. Takami S, Minami M, Katayama T, Nagata I, Namura S, Satoh M. TAK-779, a nonpeptide CC chemokine receptor antagonist, protects the brain against focal cerebral ischemia in mice. J Cereb Blood Flow Metab. 2002;22:780-784.
21. Huang S, Mills L, Mian B, Tellez C, McCarty M, Yang XD, Gudas JM, Bar-Eli M. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol. 2002;61:125-134.
22. 4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Res. 2002;62:3106-3112.
23. Carter PH. Chemokine receptor antagonism as an approach to anti-inflammatory therapy: 'just right' or plain wrong? Curr Opin Chem Biol. 2002;6:510-525.
24. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. New Eng J Med. 2000;343:1597-1602.
25. Shanahan JC, St Clair W. Tumor necrosis factor-alpha blockade: a novel therapy for rheumatic disease. Clin Immunol. 2002;103:231-242.
26. Takahashi M, Funato T, Suzuki Y, Fujii H, Ishii KK, Kaku M, Sasaki T. Chemically modified ribozyme targeting TNF-alpha mRNA regulates TNF-alpha and IL-6 synthesis in synovial fibroblasts of patients with rheumatoid arthritis. J Clin Immunol. 2002:22;228-236.
27. Nakamura S, Sugita S, Tanaka T, Ohno S. In vitro tumor necrosis factor-alpha producibility in peripheral monocytes in patients with Behçet's disease. Journal of the Japanese Ophthalmological Society. 1992;96:1282-1285.
28. Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, Sugita S, Ueno S, Yoshizaki K, Inaba G. Clinical study on infliximab for the treatment of refractory uveoretinitis in Behçet's disease. (in preparation).
29. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345(15):1098-1104.
30. Foroozan R, Buono LM, Sergott RC, Savino PJ. Retrobulbar optic neuritis associated with infliximab. Arch Ophthalmol. 2002;120:985-987.